M W Decker

Summary

Affiliation: Abbott Laboratories
Country: USA

Publications

  1. ncbi request reprint The therapeutic potential of nicotinic acetylcholine receptor agonists for pain control
    M W Decker
    Dept 4N5, Building AP 9A 3, 100 Abbott Park Rd, Abbott Park, IL 60064 6125, USA
    Expert Opin Investig Drugs 10:1819-30. 2001
  2. ncbi request reprint A-412997, a selective dopamine D4 agonist, improves cognitive performance in rats
    Kaitlin E Browman
    Neuroscience Research, Abbott Laboratories, AP9A, R4N5, 100 Abbott Park Road, Abbott Park, IL 60064 6115, USA
    Pharmacol Biochem Behav 82:148-55. 2005
  3. ncbi request reprint Effects of histamine H(3) receptor ligands GT-2331 and ciproxifan in a repeated acquisition avoidance response in the spontaneously hypertensive rat pup
    Gerard B Fox
    CNS Diseases Research, Global Pharmaceutical Research and Development, Abbott Laboratories, AP9A D4N5, Abbott Park, IL 60064, USA
    Behav Brain Res 131:151-61. 2002
  4. ncbi request reprint Differential in vivo effects of H3 receptor ligands in a new mouse dipsogenia model
    Gerard B Fox
    Neuroscience Research, Global Pharmaceutical Research and Development, Abbott Laboratories, AP9A, R4N5, Abbott Park, IL 60064 6115, USA
    Pharmacol Biochem Behav 72:741-50. 2002
  5. ncbi request reprint Preclinical profiling and safety studies of ABT-769: a compound with potential for broad-spectrum antiepileptic activity
    William J Giardina
    Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, Illinois 60064 6125, USA
    Epilepsia 46:1349-61. 2005
  6. doi request reprint The potential of neuronal nicotinic acetylcholine receptor agonists for treating CNS conditions
    Michael W Decker
    Abbott Global Pharmaceutical Research and Development, Neuroscience Drug Discovery Research, Dept R4N5, Bldg AP 9A 3, 100 Abbott Park Road, Abbott Park, IL 60064 6125, USA 1 847 937 2422 1 847 937 9195
    Expert Opin Drug Discov 3:1027-40. 2008
  7. ncbi request reprint Nicotinic acetylcholine receptor agonists: a potential new class of analgesics
    Michael W Decker
    Neuroscience Research, Drug Discovery, Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, IL 60064 6125, USA
    Curr Top Med Chem 4:369-84. 2004
  8. ncbi request reprint Identification and initial structure-activity relationships of (R)-5-(2-azetidinylmethoxy)-2-chloropyridine (ABT-594), a potent, orally active, non-opiate analgesic agent acting via neuronal nicotinic acetylcholine receptors
    M W Holladay
    Neurological and Urological Diseases Research D 47W, Abbott Laboratory, Abbott Park, Illinois 60064 3500, USA
    J Med Chem 41:407-12. 1998
  9. ncbi request reprint Differences between the antinociceptive effects of the cholinergic channel activators A-85380 and (+/-)-epibatidine in rats
    P Curzon
    Neurological and Urological Diseases Research, Pharmaceutical Products Division, Abbott Laboratories, Abbott Park, Illinois, USA
    J Pharmacol Exp Ther 287:847-53. 1998
  10. ncbi request reprint The identification of novel structural compound classes exhibiting high affinity for neuronal nicotinic acetylcholine receptors and analgesic efficacy in preclinical models of pain
    M D Meyer
    Neurological and Urological Diseases Research, Pharmaceutical Products Division, Abbott Laboratories, Abbott Park, IL 60064 6125, USA
    Eur J Pharmacol 393:171-7. 2000

Detail Information

Publications59

  1. ncbi request reprint The therapeutic potential of nicotinic acetylcholine receptor agonists for pain control
    M W Decker
    Dept 4N5, Building AP 9A 3, 100 Abbott Park Rd, Abbott Park, IL 60064 6125, USA
    Expert Opin Investig Drugs 10:1819-30. 2001
    ..However, clinical proof-of-principle studies will be required to determine if nAChR agonists are active in pathological pain...
  2. ncbi request reprint A-412997, a selective dopamine D4 agonist, improves cognitive performance in rats
    Kaitlin E Browman
    Neuroscience Research, Abbott Laboratories, AP9A, R4N5, 100 Abbott Park Road, Abbott Park, IL 60064 6115, USA
    Pharmacol Biochem Behav 82:148-55. 2005
    ..CP226269 showed a significant enhancement in the 5-trial inhibitory avoidance model. These results support a role for the dopamine D4 receptor subtype in cognition...
  3. ncbi request reprint Effects of histamine H(3) receptor ligands GT-2331 and ciproxifan in a repeated acquisition avoidance response in the spontaneously hypertensive rat pup
    Gerard B Fox
    CNS Diseases Research, Global Pharmaceutical Research and Development, Abbott Laboratories, AP9A D4N5, Abbott Park, IL 60064, USA
    Behav Brain Res 131:151-61. 2002
    ..c.) blocked the pro-cognitive effects of ciproxifan, suggesting an H(3) receptor site of action for this compound. This model is useful for evaluating the cognition/attention-enhancing potential of H(3) receptor antagonists...
  4. ncbi request reprint Differential in vivo effects of H3 receptor ligands in a new mouse dipsogenia model
    Gerard B Fox
    Neuroscience Research, Global Pharmaceutical Research and Development, Abbott Laboratories, AP9A, R4N5, Abbott Park, IL 60064 6115, USA
    Pharmacol Biochem Behav 72:741-50. 2002
    ..This new dipsogenia model provides the first in vivo behavioral evidence for possible pharmacological differences between three putative H(3) receptor inverse agonists, GT-2331 and proxyfan...
  5. ncbi request reprint Preclinical profiling and safety studies of ABT-769: a compound with potential for broad-spectrum antiepileptic activity
    William J Giardina
    Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, Illinois 60064 6125, USA
    Epilepsia 46:1349-61. 2005
    ..The objective of this study was to characterize the antiseizure and safety profiles of ABT-769 [(R)-N-(2 amino-2-oxoethyl)spiro[2,5]octane-1-carboxamide]...
  6. doi request reprint The potential of neuronal nicotinic acetylcholine receptor agonists for treating CNS conditions
    Michael W Decker
    Abbott Global Pharmaceutical Research and Development, Neuroscience Drug Discovery Research, Dept R4N5, Bldg AP 9A 3, 100 Abbott Park Road, Abbott Park, IL 60064 6125, USA 1 847 937 2422 1 847 937 9195
    Expert Opin Drug Discov 3:1027-40. 2008
    ..In addition, the neuronal nAChR partial agonist varenicline recently received regulatory approval for use in smoking cessation...
  7. ncbi request reprint Nicotinic acetylcholine receptor agonists: a potential new class of analgesics
    Michael W Decker
    Neuroscience Research, Drug Discovery, Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, IL 60064 6125, USA
    Curr Top Med Chem 4:369-84. 2004
    ....
  8. ncbi request reprint Identification and initial structure-activity relationships of (R)-5-(2-azetidinylmethoxy)-2-chloropyridine (ABT-594), a potent, orally active, non-opiate analgesic agent acting via neuronal nicotinic acetylcholine receptors
    M W Holladay
    Neurological and Urological Diseases Research D 47W, Abbott Laboratory, Abbott Park, Illinois 60064 3500, USA
    J Med Chem 41:407-12. 1998
    ..Structure-activity studies of analogues related to 4 and 5 suggest that the N-unsubstituted azetidine moiety and the 2-chloro substituent on the pyridine ring are important contributors to potent analgesic activity...
  9. ncbi request reprint Differences between the antinociceptive effects of the cholinergic channel activators A-85380 and (+/-)-epibatidine in rats
    P Curzon
    Neurological and Urological Diseases Research, Pharmaceutical Products Division, Abbott Laboratories, Abbott Park, Illinois, USA
    J Pharmacol Exp Ther 287:847-53. 1998
    ..p.) EPIB but not those of A-85380. These results suggest that A-85380 may act at multiple sites both within and outside the NRM, whereas EPIB acts largely via descending inhibitory pathways arising from the NRM...
  10. ncbi request reprint The identification of novel structural compound classes exhibiting high affinity for neuronal nicotinic acetylcholine receptors and analgesic efficacy in preclinical models of pain
    M D Meyer
    Neurological and Urological Diseases Research, Pharmaceutical Products Division, Abbott Laboratories, Abbott Park, IL 60064 6125, USA
    Eur J Pharmacol 393:171-7. 2000
    ....
  11. ncbi request reprint Effects of histamine H3 receptor antagonists in two models of spatial learning
    Victoria A Komater
    Neuroscience Research, Global Pharmaceutical Research and Development, Abbott Laboratories, AP9A, D4N5, Abbott Park, IL 60064, USA
    Behav Brain Res 159:295-300. 2005
    ..Taken together, these data suggest a role for H3 receptors in spatial learning that appears to be task-dependent...
  12. doi request reprint Assessing carrageenan-induced locomotor activity impairment in rats: comparison with evoked endpoint of acute inflammatory pain
    C Z Zhu
    Neuroscience Research, Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, USA
    Eur J Pain 16:816-26. 2012
    ..Most animal models currently used to evaluate antinociceptive efficacy of analgesics rely on the assessment of evoked pain behaviours as primary endpoints...
  13. ncbi request reprint Spinal mechanisms underlying A-85380-induced effects on acute thermal pain
    L E Rueter
    Abbott Laboratories, D47W, AP9A, 100 Abbott Park Road, Abbott Park, IL 60064 6115, USA
    Brain Res 872:93-101. 2000
    ....
  14. ncbi request reprint H3 receptor blockade by thioperamide enhances cognition in rats without inducing locomotor sensitization
    Victoria A Komater
    Neuroscience Research, Abbott Laboratories, AP9A, D4N5, Abbott Park, IL 60064, USA
    Psychopharmacology (Berl) 167:363-72. 2003
    ..Several adverse effects are associated with these drugs, however, such as agitation and abuse. H(3) receptor antagonists are under clinical investigation for ADHD...
  15. ncbi request reprint Functional characterization of the novel neuronal nicotinic acetylcholine receptor ligand GTS-21 in vitro and in vivo
    C A Briggs
    Abbott Laboratories, Abbott Park, Illinois 60064, USA
    Pharmacol Biochem Behav 57:231-41. 1997
    ..Neither was it active in the elevated plus maze anxiety model (0.19-6.2 micromol/kg.IP) in normal mice. However, GTS-21 did improve learning performance of monkeys in the delayed matching-to-sample task (32-130 nmol/kg.i.m.)...
  16. ncbi request reprint Therapeutic potential of neuronal nicotinic acetylcholine receptor agonists as novel analgesics
    M W Decker
    Neurological and Urological Diseases Research, Pharmaceutical Products Division, Abbott Laboratories, Abbott Park, IL 60064 6125, USA
    Biochem Pharmacol 58:917-23. 1999
    ....
  17. ncbi request reprint TRPV1 receptors in the CNS play a key role in broad-spectrum analgesia of TRPV1 antagonists
    M Cui
    Neuroscience Research, Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, Illinois 60064 6123, USA
    J Neurosci 26:9385-93. 2006
    ..In addition, these results demonstrate that significant CNS penetration is necessary for a TRPV1 antagonist to produce broad-spectrum analgesia...
  18. ncbi request reprint The drug-induced helplessness test: an animal assay for assessing behavioral despair in response to neuroleptic treatment
    Michael E Ballard
    Neuroscience Research, Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, IL 60064, USA
    Psychopharmacology (Berl) 190:1-11. 2007
    ..Neuroleptic dysphoria encompasses a range of unpleasant subjective responses and, as a result, is difficult to study in preclinical animal models...
  19. ncbi request reprint Reduced nicotinic receptor-mediated antinociception following in vivo antisense knock-down in rat
    R S Bitner
    Neurological and Urological Diseases Research, Pharmaceutical Products Division, Abbott Laboratories, Building AP9A LL D 4N5 60064 3500, Abbott Park, IL, USA
    Brain Res 871:66-74. 2000
    ..However, these data do not eliminate the possibility that other nicotinic subunit combinations may also play a role in antinociception produced by nAChR activation...
  20. ncbi request reprint In vitro and in vivo effects of an alpha3 neuronal nicotinic acetylcholine receptor antisense oligonucleotide
    Monique R Adams
    Department R4N5, Bldg AP9A, Abbott Laboratories Neuroscience, 100 Abbott Park Road, Abbott Park, IL 60064 6115, USA
    Brain Res Mol Brain Res 129:67-79. 2004
    ..Results of our studies suggest that Isis 106567 may be a useful in vivo tool for characterizing the functional significance of alpha3 expression in the CNS...
  21. pmc Peripheral and central sites of action for the non-selective cannabinoid agonist WIN 55,212-2 in a rat model of post-operative pain
    C Z Zhu
    Neuroscience Research, Global Pharmaceutical Research and Development, Abbott Laboratories, 100 Abbott Park Road, Abbott Park, IL 60064, USA
    Br J Pharmacol 157:645-55. 2009
    ..However, the effects of CB receptor agonists in post-operative pain remain to be investigated. Here, we characterized the anti-allodynic effects of WIN 55,212-2 (WIN) in a rat model of post-operative pain...
  22. ncbi request reprint Identification of novel H3 receptor (H3R) antagonists with cognition enhancing properties in rats
    G B Fox
    Neuroscience Research, Global Pharmaceutical Research and Development, Abbott Laboratories, AP9A, R4N5, 100 Abbott Park Rd, Abbott Park, Illinois 60064 6115, USA
    Inflamm Res 52:S31-2. 2003
  23. ncbi request reprint Selective H3 receptor (H3R) blockade: broad efficacy in cognition and schizophrenia
    G B Fox
    Neuroscience Research, Abbott Laboratories, AP9A, Global Pharmaceutical Research and Development, Abbott Park, Illinois 60064, USA
    Inflamm Res 54:S23-4. 2005
  24. ncbi request reprint Cognition enhancing effects of novel H(3) receptor (H(3)R) antagonists in several animal models
    G B Fox
    Neuroscience Research, Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, Illinois 60064, USA
    Inflamm Res 53:S49-50. 2004
  25. ncbi request reprint Antisense knockdown of the rat alpha7 nicotinic acetylcholine receptor produces spatial memory impairment
    Peter Curzon
    Neuroscience Research, Abbott Laboratories GPRD, Abbott Park, IL 60064 6115, United States
    Neurosci Lett 410:15-9. 2006
    ....
  26. ncbi request reprint Alpha4beta2 nicotinic receptor stimulation contributes to the effects of nicotine in the DBA/2 mouse model of sensory gating
    Richard J Radek
    Neuroscience Research, Global Pharmaceutical Research and Development, Abbott Laboratories, Dept R4N5, AP9A LL, 100 Abbott Park Road, Abbott Park, IL 60064, USA
    Psychopharmacology (Berl) 187:47-55. 2006
    ..This effect of nicotine has been attributed to activation of the alpha7 nicotinic acetylcholine receptor (nAChR) subtype...
  27. ncbi request reprint Effects of antipsychotics and selective D3 antagonists on PPI deficits induced by PD 128907 and apomorphine
    Min Zhang
    Neuroscience Research, Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, IL 60064, USA
    Behav Brain Res 182:1-11. 2007
    ..The possible mechanisms of D(3) receptor involvement in PPI are discussed...
  28. ncbi request reprint Evidence for tolerance following repeated dosing in rats with ciproxifan, but not with A-304121
    Jia Bao Pan
    Neuroscience Research, Abbott Laboratories, 100 Abbott Road, Abbott Park, IL 60064 6125, USA
    Life Sci 79:1366-79. 2006
    ..The implications for potential long-term treatment with H(3) receptor antagonists in CNS disorders such as ADHD are discussed...
  29. ncbi request reprint Broad-spectrum efficacy across cognitive domains by alpha7 nicotinic acetylcholine receptor agonism correlates with activation of ERK1/2 and CREB phosphorylation pathways
    Robert S Bitner
    Neuroscience Research, Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, Illinois 60064, USA
    J Neurosci 27:10578-87. 2007
    ....
  30. doi request reprint Pharmacokinetic modeling and [¹²³]5-IA-85380 single photon emission computed tomography imaging in baboons: optimization of dosing regimen for ABT-089
    Chih Liang Chin
    Advanced Technology, Global Pharmaceutical Research and Development, Abbott Park, IL 60064, USA
    J Pharmacol Exp Ther 336:716-23. 2011
    ..Our data demonstrate the feasibility of predicting plasma exposures using a two-compartment pharmacokinetic model and its potential for optimizing dosing regimens...
  31. doi request reprint Antinociceptive effects of histamine H3 receptor antagonist in the preclinical models of pain in rats and the involvement of central noradrenergic systems
    Gin C Hsieh
    Neuroscience Research, Global Pharmaceutical Research and Development, Abbott Laboratories, 100 Abbott Park Road, Abbott Park, IL 60064, USA
    Brain Res 1354:74-84. 2010
    ..Our data also provide support that selective H(3) antagonists may represent a class of agents for the treatment of pain disorders...
  32. doi request reprint In vivo pharmacological characterization of a novel selective alpha7 neuronal nicotinic acetylcholine receptor agonist ABT-107: preclinical considerations in Alzheimer's disease
    R Scott Bitner
    Neuroscience Research, Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, Illinois 60064, USA
    J Pharmacol Exp Ther 334:875-86. 2010
    ....
  33. doi request reprint ABT-594 improves performance in the 5-choice serial reaction time task under conditions of increased difficulty, sub-chronic dosing, and in poorly-performing subjects
    Eric G Mohler
    Neuroscience Research, Abbott Laboratories, 100 Abbott Park Road, Abbott Park, IL 60064 6115, USA
    Pharmacol Biochem Behav 95:146-57. 2010
    ..Moreover, a reduction in omissions was more reliably observed than improvements in accuracy, resulting in a net increase in signals successfully detected...
  34. doi request reprint Mice expressing the Swedish APP mutation on a 129 genetic background demonstrate consistent behavioral deficits and pathological markers of Alzheimer's disease
    Nathan R Rustay
    Neuroscience Disease Research, Global Pharmaceutical Research and Development, Abbott Laboratories, 100 Abbott Park Rd, Bldg AP4 2, Abbott Park, IL 60064, USA
    Brain Res 1311:136-47. 2010
    ..These results indicate that mice on the 129 genetic background may generate more consistent and robust behavioral differences, providing a useful model for testing therapeutic agents for Alzheimer's disease...
  35. doi request reprint Comparison of mechanical allodynia and the affective component of inflammatory pain in rats
    Janel M Boyce-Rustay
    Neuroscience Research, Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, IL 60064 6115, USA
    Neuropharmacology 58:537-43. 2010
    ..These studies show that methods other than reflex based measures of pain such as affective pain models could be more predictive of efficacy/potency in the clinic...
  36. doi request reprint Pharmacological modulation of movement-evoked pain in a rat model of osteoarthritis
    Prasant Chandran
    Neuroscience Research, Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, IL 60064 6115, USA
    Eur J Pharmacol 613:39-45. 2009
    ..As the model is clinically relevant, it will further enhance the mechanistic understanding of chronic arthritic joint pain and help in developing newer and better therapeutic strategies to manage osteoarthritis pain...
  37. doi request reprint Behavioral profile of P2X7 receptor knockout mice in animal models of depression and anxiety: relevance for neuropsychiatric disorders
    Ana M Basso
    Neuroscience Research, Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, IL 60064, USA
    Behav Brain Res 198:83-90. 2009
    ..These data support the relevance of pro-inflammatory cytokines in depressive-like states, and suggest that P2X(7) receptor antagonists could be of potential interest for the treatment of affective disorders...
  38. ncbi request reprint Dissociation between post-surgical pain behaviors and spinal Fos-like immunoreactivity in the rat
    Chang Z Zhu
    Neuroscience Research, Global Pharmaceutical Research, Abbott Laboratories, 100 Abbott Park Road, Abbott Park, IL 60064 3500, USA
    Eur J Pharmacol 531:108-17. 2006
    ....
  39. ncbi request reprint Effect of dopamine D3 antagonists on PPI in DBA/2J mice or PPI deficit induced by neonatal ventral hippocampal lesions in rats
    Min Zhang
    Neuroscience Research, Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, IL 60064 6115, USA
    Neuropsychopharmacology 31:1382-92. 2006
    ..In summary, the present study indicates that PPI-enhancing effects induced by antipsychotics in DBA/2J mice and in NVH-lesioned rats are unlikely to be mediated by D(3) receptors...
  40. ncbi request reprint Pharmacological properties of ABT-239 [4-(2-{2-[(2R)-2-Methylpyrrolidinyl]ethyl}-benzofuran-5-yl)benzonitrile]: II. Neurophysiological characterization and broad preclinical efficacy in cognition and schizophrenia of a potent and selective histamine H3 re
    Gerard B Fox
    Neuroscience Research, Global Pharmaceutical Research Division, Abbott Laboratories, AP9A, R4N5, Abbott Park, IL 60064 6115, USA
    J Pharmacol Exp Ther 313:176-90. 2005
    ..0 mg/kg), but not striatum. In summary, broad efficacy was observed with ABT-239 across animal models such that potential clinical efficacy may extend beyond disorders such as ADHD to include Alzheimer's disease and schizophrenia...
  41. ncbi request reprint Assessing the role of metabotropic glutamate receptor 5 in multiple nociceptive modalities
    Chang Z Zhu
    Neuroscience Research, Global Pharmaceutical Research and Development, Dept 4N5, Bldg AP9A, Abbott Laboratories, 100 Abbott Park Road, Abbott Park, IL 60064 3500, USA
    Eur J Pharmacol 506:107-18. 2004
    ..These results suggest a role for mGlu5 receptors in multiple nociceptive modalities, though CNS side effects may be a limiting factor in developing mGlu5 receptor analgesic compounds...
  42. ncbi request reprint Supraspinal and systemic administration of the nicotinic-cholinergic agonist (+/-)-epibatidine has inhibitory effects on C-fiber reflexes in the rat
    Richard J Radek
    Neuroscience Research, Global Pharmaceutical Research and Development, Abbott Laboratories, 100 Abbott Park Road, Abbott Park, IL 60064 3500, USA
    Brain Res Bull 64:323-30. 2004
    ..The inhibitory effects are consistent with the reported analgesic properties of EPIB. The excitatory effect may be related to the reported algogenic responses when EPIB is administered intrathecally...
  43. ncbi request reprint The adenosine kinase inhibitor ABT-702 augments EEG slow waves in rats
    Richard J Radek
    Neurological Diseases Research, Global Pharmaceutical Research and Development, Abbott Laboratories, 100 Abbott Park Road, Abbott Park, IL 60064 3500, USA
    Brain Res 1026:74-83. 2004
    ..These studies demonstrate that increased extracellular adenosine through AK inhibition can elicit modulatory effects on EEG slow waves via an interaction with central ADO receptor subtypes...
  44. ncbi request reprint Enhancement of prepulse inhibition of startle in mice by the H3 receptor antagonists thioperamide and ciproxifan
    Kaitlin E Browman
    Neuroscience Research, Abbott Laboratories, AP9A, 100 Abbott Park, Abbott Park, IL 60064 6115, USA
    Behav Brain Res 153:69-76. 2004
    ..Further, these data suggest that H3 receptor antagonists/inverse agonists have anti-psychotic potential for disorders such as schizophrenia...
  45. ncbi request reprint ABT-089: pharmacological properties of a neuronal nicotinic acetylcholine receptor agonist for the potential treatment of cognitive disorders
    Lynne E Rueter
    Abbott Laboratories, Neuroscience Research, R4N5, AP9A, 100 Abbott Park Rd, Abbott Park, IL 60064 6115, USA
    CNS Drug Rev 10:167-82. 2004
    ..Together these data suggest that ABT-089 is a NNR modulator with the potential for treating cognitive disorders with markedly limited adverse cardiovascular and gastrointestinal side effects...
  46. ncbi request reprint Two novel and selective nonimidazole H3 receptor antagonists A-304121 and A-317920: II. In vivo behavioral and neurophysiological characterization
    Gerard B Fox
    Neuroscience Research, Global Pharmaceutical Research and Development, Abbott Laboratories, AP9A, R4N5, 100 Abbott Park Road, Abbott Park, IL 60064 6115, USA
    J Pharmacol Exp Ther 305:897-908. 2003
    ..A-304121 and A-317920 represent a series of novel, H3R-selective piperazine amides that enhance cognition in vivo, which could offer advantages over existing H3R antagonists or cognition-enhancing agents...
  47. ncbi request reprint Antidepressant-like effect of D(2/3) receptor-, but not D(4) receptor-activation in the rat forced swim test
    Ana M Basso
    Abbott Laboratories, Neuroscience Research, Global Pharmaceutical Research and Development, Abbott Park, IL 60064, USA
    Neuropsychopharmacology 30:1257-68. 2005
    ..The pharmacological selectivity of the compounds tested suggests that the antidepressant-like effects of quinpirole are most likely mediated mainly by D(2) and to a lesser extent by D(3) but not D(4) receptors...
  48. ncbi request reprint Lack of cataleptogenic potentiation with non-imidazole H3 receptor antagonists reveals potential drug-drug interactions between imidazole-based H3 receptor antagonists and antipsychotic drugs
    Min Zhang
    Neuroscience Research, Global Pharmaceutical Research and Development, Abbott Laboratories, AP9A, R4N5, 100 Abbott Park, Abbott Park, IL 60064 6115, USA
    Brain Res 1045:142-9. 2005
    ....
  49. ncbi request reprint ABT-594 (a nicotinic acetylcholine agonist): anti-allodynia in a rat chemotherapy-induced pain model
    James J Lynch
    Neuroscience Research, Global Pharmaceutical Research and Development, Abbott Laboratories, Department R4N5, Bldg AP9A LL, 100 Abbott Park Road, Abbott Park, IL 60064 6115, USA
    Eur J Pharmacol 509:43-8. 2005
    ....
  50. ncbi request reprint Dopamine D4 receptor signaling in the rat paraventricular hypothalamic nucleus: Evidence of natural coupling involving immediate early gene induction and mitogen activated protein kinase phosphorylation
    Robert S Bitner
    Abbott Laboratories, Neuroscience Research, Abbott Park, IL 60064 3500, USA
    Neuropharmacology 50:521-31. 2006
    ..These findings provide additional evidence that the PVN may be a site of dopamine D4 receptor-mediated proerectile activity...
  51. ncbi request reprint Role of central and peripheral mGluR5 receptors in post-operative pain in rats
    Chang Z Zhu
    Neuroscience Research, Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, IL 60064 3500, USA
    Pain 114:195-202. 2005
    ..In addition, the data suggest that mGluR5 antagonists could offer a new therapeutic approach to the treatment of post-operative pain...
  52. ncbi request reprint Interleukin-1alphabeta gene-deficient mice show reduced nociceptive sensitivity in models of inflammatory and neuropathic pain but not post-operative pain
    Prisca Honore
    Abbott Laboratories, Dept R4N5, Bldg AP9A LL, 100 Abbott Park Road, Abbott Park, IL 60064, USA
    Behav Brain Res 167:355-64. 2006
    ....
  53. ncbi request reprint Effects of systemic and intracerebroventricular administration of mecamylamine, a nicotinic cholinergic antagonist, on spatial memory in rats
    M W Decker
    Neuroscience Research, Abbott Laboratories, Abbott Park, IL 60064
    Psychopharmacology (Berl) 107:530-4. 1992
    ..Thus, mecamylamine appears to impair the acquisition of spatial information in the Morris water maze but does not affect retrieval of previously acquired spatial information at comparable doses...
  54. ncbi request reprint Comparison of antinociceptive actions of standard analgesics in attenuating capsaicin and nerve-injury-induced mechanical hypersensitivity
    S K Joshi
    Abbott Laboratories, Neuroscience Research, GPRD R4N5 100 Abbott Park Road, Abbott Park, IL 60064, USA
    Neuroscience 143:587-96. 2006
    ....
  55. pmc Blockade of mGluR1 receptor results in analgesia and disruption of motor and cognitive performances: effects of A-841720, a novel non-competitive mGluR1 receptor antagonist
    O El-Kouhen
    Neuroscience Research, Global Pharmaceutical Research Division, Abbott Laboratories, Abbott Park, IL 60064, USA
    Br J Pharmacol 149:761-74. 2006
    ..To further assess the clinical potential of the blockade of metabotropic glutamate receptors (mGluR1) for the treatment of pain...
  56. ncbi request reprint Profile of nicotinic acetylcholine receptor agonists ABT-594 and A-582941, with differential subtype selectivity, on delayed matching accuracy by young monkeys
    Jerry J Buccafusco
    Department of Pharmacology and Toxicology, Alzheimer s Research Center, Medical College of Georgia, Augusta, GA 30912, USA
    Biochem Pharmacol 74:1202-11. 2007
    ....
  57. ncbi request reprint Differential effects of ciproxifan and nicotine on impulsivity and attention measures in the 5-choice serial reaction time test
    Mark Day
    Discovery Translational Medicine, Wyeth Research, 500 Arcola Road, PA 19426, USA
    Biochem Pharmacol 73:1123-34. 2007
    ..We also expanded on previous positive findings by others with ciproxifan on attention and both Wyeth and Abbott demonstrate for the first time decreased impulsivity with this mechanism...
  58. doi request reprint Glutamatergic contributions to nicotinic acetylcholine receptor agonist-evoked cholinergic transients in the prefrontal cortex
    Vinay Parikh
    Department of Psychology, University of Michigan, Ann Arbor, Michigan 48109 1043, USA
    J Neurosci 28:3769-80. 2008
    ..Glutamatergic mechanisms necessarily mediate the cholinergic effects of nAChR agonists in the prefrontal cortex...
  59. pmc Neuronal nicotinic receptor agonists for the treatment of attention-deficit/hyperactivity disorder: focus on cognition
    Timothy E Wilens
    Massachusetts General Hospital, Pediatric Psychopharmacology Research Unit, Yawkey Center for Outpatient Care Yaw 6A, Boston, MA 02114, USA
    Biochem Pharmacol 74:1212-23. 2007
    ..Further understanding of the effects of novel neuronal nAChR agonists on specific aspects of cognitive functioning in ADHD is required to assess the full potential of this approach...